Comment on "A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder"'

被引：0
作者：
Wang, Chenxi [1 ]
Tian, Huichuan [1 ]
Shang, Jin [2 ]
机构：
[1] Macau Univ Sci & Technol, Fac Chinese Med, Taipa 999078, Macao, Peoples R China
[2] Hubei Univ Tradit Chinese Med, Sch Pharm, Wuhan 430065, Peoples R China
来源：
CNS DRUGS | 2025年 / 39卷 / 02期
关键词：
D O I：
10.1007/s40263-024-01152-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：209 / 210
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies
    Thase, Michael E.
    Zhang, Peter
    Weiss, Catherine
    Meehan, Stine Rasmussen
    Hobart, Mary
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) : 1907 - 1916
  • [42] Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder
    Filippov, G.
    Christens, P. F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S325 - S325
  • [43] Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study
    Yamaguchi, Yukie
    Takatsu, Nobumichi
    Ootaki, Kenji
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2020, 47 (06) : 569 - 577
  • [44] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Komatsu, Norio
    Kirito, Keita
    Shimoda, Kazuya
    Ishikawa, Takayuki
    Ohishi, Kohshi
    Ohyashiki, Kazuma
    Takahashi, Naoto
    Okada, Hikaru
    Amagasaki, Taro
    Yonezu, Toshio
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 309 - 317
  • [45] Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder
    Andersen, SW
    Clemow, DB
    Corya, SA
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (11) : 1468 - 1476
  • [46] Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study
    Tanaka, Yoshiya
    Curtis, Paula
    DeRose, Kathleen
    Kurrasch, Regina
    Kinoshita, Kyoko
    Tanaka, Rika
    Yamazaki, Yumi
    Roth, David A.
    MODERN RHEUMATOLOGY, 2023, 33 (01) : 122 - 133
  • [47] Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open-label extension study - Editorial comment
    Djavan, B
    EUROPEAN UROLOGY, 2002, 41 (01) : 60 - 61
  • [48] Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
    Wade, Alan G.
    Crawford, Gordon M.
    Yellowlees, Ann
    BMC PSYCHIATRY, 2011, 11
  • [49] Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
    Alan G Wade
    Gordon M Crawford
    Ann Yellowlees
    BMC Psychiatry, 11
  • [50] FLEXIBLE-DOSE BREXPIPRAZOLE AS MAINTENANCE TREATMENT IN ADOLESCENTS WITH SCHIZOPHRENIA: A LONG-TERM, MULTICENTER, OPEN-LABEL STUDY
    Chumki, Sanjeda
    Hefting, Nanco
    Wang, Fan
    Ward, Caroline
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2022, 61 (10) : S141 - S141
12345